
Ceva Sante Animale
Ceva Sante Animale S.A. engages in the research, development, production.
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Growth Equity non VC | ||
N/A | - | ||
* | €5.5b Valuation: €9.2b | Growth Equity non VC | |
Total Funding | - |
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 18 % | 21 % | 8 % | 8 % | 7 % | 14 % | 3 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 20 % | 22 % | 26 % | 17 % | 22 % | 29 % | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 8 % | 12 % | 13 % | 4 % | 5 % | 12 % | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
The story of Ceva Santé Animale begins not with a startup, but with a carve-out. In 1999, a merger between French pharmaceutical giants Sanofi and Synthélabo created a new entity that decided to divest its animal health division. This is where our story starts. A group of the division's senior executives, led by CEO Marc Prikazsky, saw an opportunity. They orchestrated a leveraged management buyout (LBO), buying the business they knew so well and establishing Ceva Santé Animale as an independent company. From its headquarters in Libourne, France, Ceva focused on research, development, and marketing of pharmaceuticals and vaccines for a wide range of animals—from pets to poultry, ruminants, and swine. This broad focus allowed the company to build a diverse and resilient business. Instead of a typical venture capital path, Ceva's journey was defined by a series of management-led buyouts. A pivotal moment came in 2007 when, during a third financing round, the company's management and employees became the majority shareholders, giving the people who ran the business a controlling stake in its future. This unique ownership structure fueled aggressive growth. Ceva expanded by acquiring companies and laboratories across the globe, averaging three acquisitions a year and growing its revenue significantly. By 2017, the company had broken the €1 billion sales mark, cementing its position as a major global player in the animal health industry. Today, Ceva stands as the world's fifth-largest animal health company, a testament to the power of a dedicated management team taking control of its own destiny.
Tech stack
Investments by Ceva Sante Animale
Edit

